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Abstract
Objective: Rosiglitazone was found associated with approximately a 43% increase in risk of acute myocardial infarction
(AMI) in a two meta-analyses of clinical trials. Our objective is to estimate the magnitude of the association in real-world
patients previously treated with metformin.
Research Design and Methods: We conducted a nested case control study in British Columbia using health care databases
on 4.3 million people. Our cohort consisted of 158,578 patients with Type 2 diabetes who used metformin as first-line drug
treatment. We matched 2,244 cases of myocardial infarction (AMI) with up to 4 controls. Conditional logistic regression
models were used to estimate matched odds ratios for AMI associated with treatment with rosiglitazone, pioglitazone and
sulfonylureas.
Results: In our cohort of prior metformin users, adding rosiglitazone for up to 6 months was not associated with an
increased risk of AMI compared to adding a sulfonylurea (odds ratio [OR] 1.38; 95% confidence interval [CI], 0.91–2.10), or
compared to adding pioglitazone (OR for rosi versus pio 1.41; 95% CI, 0.74–2.66). There were also no significant differences
between rosiglitazone, pioglitazone and sulfonylureas for longer durations of treatment. Though not significantly different
from sulfonylureas, there was a transient increase in AMI risk associated with the first 6 months of treatment with a glitazone
compared to not using the treatment (OR 1.53; 95% CI, 1.13–2.07)
Conclusions: In our British Columbia cohort of patients who received metformin as first-line pharmacotherapy for Type 2
diabetes mellitus, further treatment with rosiglitazone did not increase the risk of AMI compared to patients who were
treated with pioglitazone or a sulfonylurea. Though not statistically significantly different compared from each other, an
increased risk of AMI observed after starting rosiglitazone or sulfonylureas is a matter of concern that requires more
research.
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Introduction
Rosiglitazone (AvandiaH) is a peroxisome-proliferator-activated
receptor c agonist used to treat patients with Type 2 diabetes
mellitus.Themedicationistakentolowerandcontrolbloodglucose.
InJune2007,meta-analysisofrandomizedclinicaltrialdatafounda
statistically significant 42%–43% increase in risk of myocardial
infarction (AMI) associated with rosiglitazone treatment [1,2]. The
meta-analyses did not show an increased risk of AMI compared
separately to placebo, metformin, sulfonylureas or insulin. Epide-
miologic studies have reported conflicting results. One study
reported an increased risk of AMI with rosiglitazone treatment
compared to treatment with metformin and sulfonylurea mono-
therapy in older patients with diabetes [3]. Another study did not
find a significant association with AMI compared to treatment with
metformin or sulfonylurea [4]. The relationship between rosiglita-
zone andAMIremainscontroversial.Atleastone studyshowedthat
the Nissen meta-analysis could have overestimated the cardiovas-
cular risks of rosiglitazone by excluding trials with zero events [5].
We investigated the association between AMI and treatment
with rosiglitazone, pioglitazone and sulfonylureas in patients who
added or switched to these drugs from metformin as first-line drug
treatment. British Columbia (BC), Canada, provided a unique
opportunity for this kind of analysis because, since late 1995, its
comprehensive PharmaNet database has captured all prescriptions
dispensed at community pharmacies to its large and stable
population (4.3 million in 2006). Since that time, approximately
77% of patients with Type 2 diabetes mellitus were started on
metformin as first-line drug treatment.
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We obtained ethics approval from the University of British
Columbia Clinical Research Ethics Board and we were not
required to obtain informed consent from patients included in the
study. All data were analyzed anonymously.
Data
The PharmaNet database contains all prescriptions, regardless
of payer, dispensed at community pharmacies in BC since the
autumn of 1995. We expect that underreporting and misclassi-
fication are very low because the PharmaNet system performs
data quality checks. Prescriptions were linked by unique personal
health number to BC Ministry of Health databases for
hospitalizations, medical services registration, and family income.
Data on hospitalizations were collected by the Canadian Institute
for Health Information, which collects hospitals data for all
Canadian provinces, including Ontario where the data have
been evaluated for accuracy [6]. The completeness of similar
databases in other North American jurisdictions has been studied
[6–10] but we are unaware of any such analyses in British
Columbia.
Source Population and Cohort
We conducted a nested case-control study. The source
population included all residents of BC at any time between
January 1997 and March 2007 who were registered for
provincial medical coverage for at least one year. Federally
insured patients (aboriginals, prisoners and military personnel),
4% of the provincial population, were excluded from the source
population because we did not have permission to use those data.
The source population numbered 4.1 million in 2006 [11]. We
assembled a cohort of patients from the source population who
initiated metformin between January 1, 1997 and March 31,
2007. Initiation was defined as a pharmacy dispensing for
metformin without another metformin dispensing in the previous
365 days. Patients were excluded if they received other oral
antidiabetic medications or insulin within 365 days before
starting metformin, or if they emigrated from BC or died prior
to May 1, 2003.
The study period ran from May 1, 2003 to March 31, 2007.
The study period was chosen based on the availability of family-
specific income data starting in May of 2003. Glitazones cost more
than metformin and sulfonylureas, and the BC Ministry of Health
covered them only after failure or intolerance to metformin and
two sulfonylureas. We adjusted for income because use of
glitazones without insurance coverage could be correlated with a
patient’s socioeconomic status and risk of AMI.
Myocardial Infarction Cases
We extracted patients from the BC Ministry of Health
hospitalizations database who were admitted to hospital with
acute myocardial infarction (ICD-9 410) recorded as the primary
reason for the admission. A validation study of the U.S. Medicare
database found that hospitalizations with an ICD-9 code of 410 as
the primary or secondary diagnosis code had a positive predictive
value for AMI of 0.94 [12]. Cohort members were eligible for
selection as cases after the latest date of May 1, 2003 or initiation
of metformin, and until the earliest date of the occurrence of the
outcome, death, emigration from BC, or March 31, 2007. We
estimated that 2,100 AMI cases and 8,400 controls would be
needed to observe an odds ratio of 1.40 with 80% power, a Type-I
error of 0.05, and an exposure prevalence of 3.5%.
Controls and Matching
Patients were eligible to be controls if they were in the cohort
of metformin initiators and were still contributing person-time at
risk for the outcome at the time of the AMI of their matching
case. Each case was demographically matched with up to 4
controls. Patients were matched on age (in 5-year categories), sex,
number of family members, enrollment in supplemental health
coverage, and family income in bands of $5,000 for incomes
under $100,000, and bands of $25,000 for incomes above
$100,000. Number of family members and income were used to
match cases to controls that had similar abilities to pay for
prescription drugs. Controls were not matched on cardiovascular
risk factors as these could be intermediates in the causal pathway
between medication use and AMI. Controls were selected
randomly using incidence density sampling from patients with
the same matching factors as the cases in ascending order of
random number assignment.
Exposure to Oral Antidiabetic Medications
We evaluated exposure to the glitazones (rosiglitazone and
pioglitazone) and the sulfonylureas (acetohexamide, chlorprop-
amide, gliclazide, glimepiride, glyburide, tolbutamide). We
extracted all prescriptions for these drugs before the event date
(cases) or index date (controls). We divided exposure into current
accumulated use and past use. Exposure within 90 days of the
index date was defined as current exposure. All preceding
exposure was summed as current cumulative exposure so long as
no interruption in use of greater than 90 days occurred.
Exposure prior to any 90 day interruption was categorized as
past exposure.
Case-Control Analysis
We used conditional logistic regression models to estimate the
matched odds ratios for AMI. We estimated odds ratios related to
5 exposures: rosiglitazone, pioglitazone, either rosiglitazone or
pioglitazone, any sulfonylurea, and glyburide, which was the most
commonly prescribed sulfonylurea in BC. Associations with
exposure duration were modeled using predefined categories of
1 to 6, 7 to 12, 13 to 24, and .24 months of current cumulative
exposure. Past exposure was modeled as a binary indicator
variable.
In addition to the demographic matching factors, odds ratios
were adjusted for duration of diabetes (counted from the earliest
date of a diagnosis for diabetes or initiation of metformin) and the
following covariates within 5 years of the index date: congestive
heart failure (CHF: hospitalization for ICD-9 428 or a physician
visit for same plus a prescription for furosemide), angiography,
coronary artery bypass graft (CABG), percutaneous transluminal
angioplasty (PTCA), ischemic stroke (hospitalization for ICD-9
433, 434 or 436), transient ischemic attack (hospitalization for
ICD-9 435), angina (ICD-9 412–414), prior AMI, renal disease
(ICD-9 584–586, 403–404). The following covariates were
measured and adjusted for within one year of the index date:
Romano comorbidity score (meant to adjust for confounding by
concomitant illnesses by assigning weights to a patient’s ICD-9
diagnoses and summing those weights into a single score) [13],
exposure to nitrates, statins, angiotensen II converting enzyme
inhibitors or receptor blockers, thiazide diuretics, calcium channel
blockers, beta blockers, clopidogrel, digoxin, warfarin, insulin, and
past use of metformin, glitazones and sulfonylureas, and total
number of distinct drugs taken. Including previous drug use
enabled the analysis to adjust for past treatment failures and
successes.
Rosiglitazone and MI
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There were 189,563 patients from the source population who
initiated metformin between January 1, 1997 and March 31, 2007.
Of those, 158,578 remained eligible for cohort entry. We
identified 2,244 cases of acute myocardial infarction in the cohort
during the follow-up period. The cases were matched to 8,903
controls. Characteristics of the cases and controls are shown in
Table 1. As expected, the groups were demographically similar
and differed significantly with respect to cardiovascular risk
factors. A higher proportion of cases had renal disease, prior
AMI, angina, CHF, and prior procedures such as CABG,
coronary catheterization and PTCA. There were 7.7% of cases
and 7.1% of controls that used a glitazone within a year of their
index date. Similar proportions of cases and controls used
metformin in the previous year (80%). Forty percent of cases
and 32% of controls received a sulfonylurea.
Baseline characteristics in the study population were also
compared to identify potential confounders associated with
treatment. Age, sex and income were significantly associated with
Table 1. Characteristics of Type II Diabetes Patients with Myocardial Infarction and Their Matched Controls*.
Variable Cases of Acute
Myocardial Infarction Controls Odds Ratio
(N=2,244) (N=8,903) (95% CI)
Age,mean(SD), 70 (12) 70 (12) 1.00 (0.99–1.01)
Female (%) 806 (36) 3,201 (36) 1.00 (0.90–1.11)
Income category (%){
$0–$24,999 605 (27) 2,369 (27) 1.02 (0.92–1.14)
$25,000–$49,999 759 (34) 2,978 (33) 1.02 (0.93–1.12)
$50,000–$74,999 338 (15) 1,363 (15) 0.98 (0.87–1.11)
$75,000–$99,999 121 (5) 482 (5) 0.99 (0.82–1.20)
.=$100,000 72 (3) 271 (3) 1.04 (0.81–1.33)
Unknown 349 (16) 1,440 (16) 0.96 (0.85–1.08)
Romano score mean (SD){ 2.0 (1.7) 1.5 (1.3) 1.18 (1.15–1.21)
Diabetes duration, mean (SD), y 6.9 (4.4) 6.4 (4.2) 1.03 (1.02–1.04)
Renal disease 142 (6) 244 (3) 1.97 (1.64–2.37)
Acute myocardial infarction1 190 (8) 293 (3) 2.19 (1.87–2.57)
Angina1 1,201 (54) 2,854 (32) 2.18 (1.99–2.39)
Congestive heart failure1 788 (35) 1,964 (22) 1.85 (1.68–2.05)
Coronary artery bypass graft1 43 (2) 209 (2) 0.88 (0.64–1.20)
Coronary catheterization1 363 (16) 742 (8) 1.81 (1.60–2.05)
PTCA1 173 (8) 288 (3) 2.01 (1.69–2.39)
Drug use in previous yearI
Glitazone 173 (8) 631 (7) 1.10 (0.92–1.30)
Metformin 1,798 (80) 7,081 (80) 1.02 (0.91–1.14)
Sulfonylurea 907 (40) 2,825 (32) 1.38 (1.26–1.51)
ACE Inhibitor 1,241 (55) 4,565 (51) 1.12 (1.02–1.22)
NSAIDs 606 (27) 2,170 (24) 1.10 (1.00–1.22)
Beta blockers 1,641 (73) 5,985 (67) 1.30 (1.17–1.44)
Thiazide diuretics 743 (33) 2,986 (34) 1.00 (0.91–1.10)
Digoxin 238 (11) 515 (6) 1.67 (1.44–1.94)
Spironolactone 165 (7) 365 (4) 1.64 (1.38–1.94)
Statins 1,104 (49) 4,096 (46) 1.11 (1.02–1.22)
Calcium channel blockers 735 (33) 2,157 (24) 1.42 (1.29–1.57)
Clopidogrel 248 (11) 392 (4) 2.09 (1.81–2.42)
No. drugs prescribed (SD) 11 (6.4) 9 (5.4) 1.05 (1.04–1.06)
No. Physician Visits (SD) 21 (17) 18 (14.6) 1.01 (1.00–1.01)
*Odds ratios have been adjusted for matching variables (age in 5-year groupings, sex, family income band in $5,000 dollar increments, number of family members, and
existence of supplemental coverage). CI denotes confidence interval.
{Net family income band in Canadian dollars from the most recent federal income tax return (1 Canadian dollar=1.2 US dollars).
{Romano commorbidity score calculated using data from 365 days prior to the index date.
1History within 5 years prior to the index date.
IDispensing of a drug within 365 days prior to index date.
doi:10.1371/journal.pone.0006080.t001
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on those demographic factors. Patients exposed to glitazones and
sulfonylureas had diabetes for approximately one year longer on
average than unexposed patients. Prior AMI was associated with
glitazone exposure but potential for confounding was low because
the prevalence was low (3% of exposed patients and 4% of
unexposed patients).
As shown in Table 3, the risk of AMI in the first 6 months of
treatment with rosiglitazone was not significantly different
compared to 6 months of treatment with sulfonylureas (odds ratio
1.38; 95% CI, 0.91–2.10) or pioglitazone (odds ratio 1.41; 95%
CI, 0.74–2.66). There were also no significant differences between
OADs for longer durations of use. However, within-drug analyses
which studied the association between adding a treatment
compared to not adding it showed transient increases in AMI
risk (Table 4). Addition of glitazone therapy for up to 6 months
duration was associated with a 50% increased risk of AMI
compared to not adding a glitazone (odds ratio 1.53; 95%
confidence interval [CI] 1.13–2.07). This association was observed
with rosiglitazone (odds ratio 1.71; 95% CI, 1.19–2.46) but not for
pioglitazone (odds ratio 1.21; 95% CI, 0.72–2.04) although the
two confidence intervals overlapped. Exposures longer than 6
months were not associated with significant changes in risk of AMI
for either rosiglitazone or pioglitazone, separately or combined.
Unlike the glitazones, however, elevated risk associated with
sulfonylurea use was also observed for treatment durations
Table 2. Characteristics of Study Patients (Cases and Controls).
Variable Rosiglitazone Pioglitazone Sulfonylurea
Exposed Unexposed Exposed Unexposed Exposed Unexposed
(N=462) (N=10,685) (N=235) (N=10,912) (N=1,612) (N=9,535)
Age, mean (SD) 66 (11) 70 (12) 66 (12) 70 (12) 69 (12) 70 (12)
Female (%) 113 (24) 3,894 (36) 69 (29) 3,938 (36) 581 (36) 3,426 (36)
Income category (%)*
$0–$24,999 85 (18) 2,889 (27) 40 (17) 2,934 (27) 477 (30) 2,497 (26)
$25,000–$74,999 147 (32) 3,590 (34) 82 (35) 3,655 (33) 521 (32) 3,216 (34)
$75,000–$99,999 116 (25) 1,585 (15) 42 (18) 1,659 (15) 238 (15) 1,463 (15)
.=$100,000 52 (11) 551 (5) 31 (13) 572 (5) 82 (5) 521 (5)
Unknown 37 (8) 318 (3) 19 (8) 324 (3) 48 (3) 295 (3)
Romano score mean (SD){ 1.7 (1.4) 1.6 (1.4) 1.5 (1.1) 1.6 (1.4) 1.8 (1.5) 1.6 (1.4)
Diabetes duration, mean (SD), y 7.7 (4) 7.5 (4.2) 7.7 (4) 6.5 (4.2) 7.5 (4.2) 6.3 (4.2)
Renal disease 11 (2) 375 (4) 4 (2) 382 (4) 88 (5) 298 (3)
Acute myocardial infarction{ 7 (2) 476 (4) 11 (5) 472 (4) 67 (4) 416 (4)
Angina{ 175 (38) 3,880 (36) 90 (38) 3,965(36) 595 (37) 3,460 (36)
Congestive heart failure{ 108 (23) 2,644 (25) 55 (23) 2,697 (25) 438 (27) 2,314 (24)
Coronary artery bypass graft{ 9 (2) 243 (2) 8 (3) 244 (2) 32 (2) 220 (2)
Coronary catheterization{ 40 (9) 1,065 (10) 28 (12) 1,077 (10) 163 (10) 942 (10)
PTCA{ 16 (3) 445 (4) 10 (4) 451 (4) 76 (5) 385 (4)
Drug Use in Past Year1
Glitazone 460 (100) 344 (3) 235 (100) 571 (5) 206 (13) 598 (6)
Metformin 361 (78) 8,518 (80) 188 (80) 8,691 (80) 1,309 (81) 7,570(79)
Sulfonylurea 267 (58) 3,465 (32) 128 (54) 3,604 (33) 1,612 (100) 2,121 (22)
ACE Inhibitor 262 (57) 5,544 (52) 145 (62) 5,661 (52) 962 (57) 4,880 (51)
NSAIDs 111 (24) 2,665 (25) 51 (22) 2,725 (25) 416 (26) 2,360 (25)
Beta blockers 352 (76) 7,274 (68) 191 (81) 7,435 (68) 1,214 (75) 6,412 (67)
Thiazide diuretics 207 (45) 3,522 (33) 80 (34) 3,649 (33) 593 (37) 3,136 (33)
Digoxin 24 (5) 729 (7) 17 (7) 736 (7) 123 (8) 630 (7)
Spironolactone 27 (6) 503 (5) 14 (6) 516 (5) 85 (5) 445 (5)
Statins 289 (63) 4,911(46) 146 (62) 5,054 (46) 854 (53) 4,346 (46)
Calcium channel blockers 140 (30) 2,752 (26) 53 (23) 2,839 (26) 455 (28) 2,437 (26)
Clopidogrel 25 (5) 615 (6) 13 (6) 627 (6) 115 (7) 525 (6)
No. drugs prescribed (SD) 11 (5.2) 9 (5.7) 11 (4.4) 9 (5.7) 11 (5.3) 9 (5.7)
No. Physician Visits (SD) 19 (15.2) 18 (15.2) 19 (13.9) 18 (15.2) 19 (14.9) 18 (15.2)
*Net family income in Canadian dollars (1 Canadian dollar=1.2 US dollars).
{Romano commorbidity score calculated using data from 365 days prior to the index date.
{History within 5 years prior to the index date.
1Dispensing of a drug within 365 days prior to index date.
doi:10.1371/journal.pone.0006080.t002
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and over 24 months (odds ratio 1.45; 95% CI, 1.17–1.81). A
separate analysis of glyburide alone showed similar results as for all
sulfonylureas as a class.
Discussion
This study provides comparative data on the relationship
between myocardial infarction and treatment with glitazones and
sulfonylureas in patients who switched to or added those drugs to
first-line treatment with metformin. Adding rosiglitazone treat-
ment did not significantly increase risk of AMI compared to
adding pioglitazone or a sulfonylurea. Patients in our study were
drawn from the broadest population of glitazone patients studied
to date. Our results are generalizable to patients with Type 2
diabetes who received metformin as first-line drug treatment.
From our data, and for the 10-year period ending in March 2007,
we estimated that metformin was used as first-line drug treatment
in 77% of patients with Type 2 diabetes.
There is evidence from trials like ACCORD [14] and UGDP
[15] that more intensive hypoglycemic therapy increases cardio-
vascular risk. The purpose of the analysis in Table 4 was to
estimate temporal associations within each drug to see if increased
risk was generally associated with more treatment with OADs, an
effect that could have been masked in the analysis of drug-to-drug
comparisons in Table 3. In Table 4, an increased risk of AMI was
not observed with pioglitazone, which is consistent with the null
result for pioglitazone and MI reported in a meta-analysis of
randomized trials of pioglitazone [16]. However, our power to
detect an association was lower because the use of pioglitazone in
the source population was half that of rosiglitazone. Also in
Table 4, addition of sulfonylurea therapy was associated with a
significant 25% increase in risk that appeared to be independent of
duration of use. The increase associated with the addition of
rosiglitazone or a sulfonylurea could be clinically significant and
suggests that either worsening glycemic control (which leads to
treatment intensification) increases cardiovascular risk, or, alter-
natively, that increased risk is a result of more intensive therapy as
shown for CV death but not AMI in the ACCORD trial [14]. It is
tempting to assume that former explanation is correct, but
defending that assumption requires selective use of evidence or
at least a clear refutation of evidence from clinical trials, meta-
analyses and observational studies that lend merit to the latter
explanation. In our opinion, increased risk of cardiovascular
events as a consequence of treatment with any OAD is a credible
hypothesis that requires more research.
The Nissen meta-analysis reported an overall 43% increase
(95% CI, 3%–98%) in AMI events in patients treated with
rosiglitazone compared to controls on various treatments
including placebo [1]. A direct comparison of our analysis with
that overall result is not simple because only 35% of patients in
the meta-analysis received metformin compared to 80% of
patients in our study in the previous year. However, a subgroup
comparison in the Nissen meta-analysis of trials that used
metformin as a control showed an odds ratio of 1.14 (95% CI,
0.70–1.86). The odds ratio we observed (1.14 from Table 4) was
within the 95% confidence interval of the Nissen meta-analysis
and was also not statistically significant. An interim analysis of
the Rosiglitazone Evaluated for Cardiovascular Outcome (RE-
CORD) trial also reported a similar hazard ratio to ours for AMI
of 1.16 (95% CI, 0.75–1.81) for rosiglitazone (plus metformin or
plus sulfonylurea) compared to treatment with metformin plus
sulfonylurea [17].
Our results for rosiglitazone are close to the estimates reported
in an observational analysis by McAfee. [4]. Their study reported
hazard ratios for MI outcomes of 1.19 for rosiglitazone compared
to metformin, and a hazard ratio of 0.79 for rosiglitazone
Table 3. Risk of Myocardial Infarction for Rosiglitazone Compared to Pioglitazone and Sulfonylureas in Patients Who Received
Metformin as First-Line Drug Treatment.
Rosiglitazone Comparator
Current Cumulative
Exposure (months){
Unadjusted Odds Ratio for
Rosiglitazone (95% CI){*
Adjusted Odds Ratio for
Rosiglitazone (95% CI)1*
Sulfonylureas 1–6 1.17 (0.79–1.74) 1.38 (0.91–2.10)
7–12 0.84 (0.50–1.41) 0.75 (0.44–1.27)
13–24 0.59 (0.33–1.06) 0.76 (0.41–1.38)
.24 0.60 (0.37–0.96) 0.68 (0.41–1.12)
Overall 0.81 (0.63–1.03) 0.90 (0.69–1.17)
Pioglitazone 1–6 1.39 (0.76–2.52) 1.41 (0.74–2.66)
7–12 0.89 (0.40–1.97) 0.95 (0.41–2.22)
13–24 0.64 (0.28–1.45) 0.68 (0.29–1.60)
.24 0.88 (0.41–1.89) 0.93 (0.41–2.11)
Overall 0.97 (0.67–1.40) 1.00 (0.67–1.49)
*CI denotes confidence interval.
{The current cumulative exposure period is the number of months of continuous exposure prior to the event (for cases) or matched index date (controls). Cumulative
current exposure includes continuous drug use up until the index date. Exposure that was accumulated prior to any lapse in therapy of greater than 90 days was
defined as past exposure.
{Odds ratios have been adjusted for matching variables (age in 5-year groupings, sex, family income band in $5,000 dollar increments, number of family members, and
existence of supplemental coverage).
1Odds ratios have been adjusted for (in addition to the matching variables) the time since initiation of metformin, the following within 5 years of the index date:
congestive heart failure (hospitalization for ICD-9 428 or a physician visit for same plus a prescription for furosemide), angiography, coronary artery bypass graft,
percutaneous transluminal angioplasty, ischemic stroke (hospitalization for ICD-9 433, 434, or 436), transient ischemic attack (hospitalization for ICD-9 435), angina
(ICD-9 412–414), prior AMI, renal disease (ICD-9 584–586, 403–404); and the following within one year of index: Romano comorbidity score, exposure to nitrates, statins,
angiotensen II converting enzyme inhibitors or receptor blockers, thiazide diuretics, calcium channel blockers, beta blockers, clopidogrel, digoxin, warfarin, insulin, and
past use of metformin, glitazones and sulfonylureas.
doi:10.1371/journal.pone.0006080.t003
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estimated odds ratios of 1.14 and 0.90, respectively.
In another recent Canadian study of cardiovascular outcomes
among patients older than 65 years in Ontario, current treatment
with a glitazone (rosiglitazone or pioglitazone) was associated with
an odds ratio of 1.40 (95% CI, 1.05–1.86) for AMI compared to
patients receiving other OAD medications [3]. The effect size may
have been greater than in other studies because, as the authors
stated, ‘‘our TZD treated population may represent an older and
more select population of patients with more advanced diabetes
because under Ontario Drug Benefit reimbursement criteria, most
of these patients will have failed or had a contraindication to other
drugs.’’
As with most population-based outcomes studies of prescription
drugs, our study was susceptible to channeling bias, which is a type
of confounding by indication where marketing leads to sicker
patients being more likely to be early users of new drugs. The
expected direction of such a bias is to increase the association
between glitazones and AMI. We cannot say if our study was more
influenced by such forces than other epidemiologic studies of the
glitazones, but the 6-month odds ratios for the glitazones (Table 4)
increased after multivariable adjustment, which suggests that we
Table 4. Within-Drug Comparison of Glitazone Exposure and Sulfonylurea Exposure in Myocardial Infarction Cases and Matched
Controls who received Metformin as First-Line Drug Therapy.
Oral Diabetes
Medication
Current Cumulative
Exposure (months){
No. of Cases
(n=2,244)
No. of Controls
(n=8,903)
Unadjusted Odds
Ratio{
Adjusted Odds Ratio
(95% CI)1*
Glitazones 1–6 57 157 1.45 1.53 (1.13–2.07)
7–12 31 110 1.12 1.00 (0.67–1.47)
13–24 26 120 0.86 0.97 (0.64–1.48)
.24 35 160 0.87 0.99 (0.68–1.45)
Overall 149 547 1.09 1.14 (0.94–1.38)
Past Use 124 427 1.11 0.93 (0.75–1.14)
Rosiglitazone 1–6 18 64 1.12 1.71(1.19–2.46)
7–12 10 33 1.20 0.97(0.61–1.54)
13–24 12 42 1.13 0.83(0.47–1.45)
.24 11 45 0.97 0.99(0.63–1.55)
Overall 51 184 1.10 1.14(0.90–1.43)
Past Use 41 134 1.19 0.94(0.74–1.19)
Pioglitazone 1–6 18 64 1.12 1.21 (0.72–2.04)
7–12 10 33 1.20 1.02 (0.50–2.07)
13–24 12 42 1.13 1.21 (0.64–2.30)
.24 11 45 0.97 1.21 (0.54–2.10)
Overall 51 184 1.10 1.21 (0.82–1.57)
Past Use 41 134 1.19 1.21 (0.64–1.29)
Sulfonylureas 1–6 121 368 1.32 1.24 (1.01–1.52)
7–12 80 257 1.24 1.29 (1.01–1.65)
13–24 92 303 1.21 1.09 (0.87–1.38)
.24 107 284 1.52 1.45 (1.17–1.81)
Overall 400 1,212 1.31 1.26 (1.12–1.43)
Past Use 585 1,959 1.21 1.09 (0.97–1.21)
Glyburide 1–6 84 255 1.32 1.37 (1.08–1.74)
7–12 58 181 1.28 1.38 (1.03–1.83)
13–24 65 212 1.22 1.07 (0.81–1.41)
.24 73 196 1.49 1.43 (1.11–1.85)
Overall 280 844 1.32 1.31 (1.13–1.51)
Past Use 507 1,680 1.21 1.07 (0.96–1.21)
*CI denotes confidence interval.
{The current cumulative exposure period is the number of months of continuous exposure prior to the event (for cases) or matched index date (controls). Cumulative
current exposure includes continuous drug use up until the index date. Exposure that was accumulated prior to any lapse in therapy of greater than 90 days was
defined as past exposure.
{Odds ratios have been adjusted for matching variables (age in 5-year groupins, sex, family income band in $5,000 dollar increments, number of family members, and
existence of supplemental coverage).
1Odds ratios have been adjusted for (in addition to the matching variables) time since initiation of metformin, the following within 5 years of the index date: congestive
heart failure, angiography, coronary artery bypass graft, percutaneous transluminal angioplasty, ischemic stroke, transient ischemic attack, angina, prior AMI, renal
disease; and the following within one year of index: Romano comorbidity score, exposure to nitrates, statins, angiotensen II converting enzyme inhibitors or receptor
blockers, thiazide diuretics, calcium channel blockers, beta blockers, clopidogrel, digoxin, warfarin, insulin, and past use of metformin, glitazones and sulfonylureas.
doi:10.1371/journal.pone.0006080.t004
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that patients with deteriorating health led their physicians to add
OADs, and our results could have been biased upwards if such
deteriorations were not captured in our claims data but affected
AMI risk. Specifically, among patients with diabetes who fluctuate
between periods of good and poor control of their blood sugar,
glitazones would be initiated in poor periods when risk of AMI
might be transiently higher. Therefore, the transient elevation in
AMI risk after initiation of rosiglitazone may, at least in part, be
due to confounding by indication. Direct comparison of glitazone
starters and sulfonylurea starters would be less biased because both
classes of drugs would tend to be initiated in periods of poor
control. We expect that our within-drug analysis of adding/
switching treatment versus not adding/switching treatment
(Table 4) would be more vulnerable to this kind of bias than our
analysis using comparator drugs (Table 3).
Exposure definitions (current or past use) could not be measured
with certainty since dispensing records were used rather than a
direct measure of consumption. Some patients dispensed medica-
tions may not have taken their drug, causing them to mistakenly
be classified as exposed instead of unexposed. So long as the
sensitivity and specificity of the exposure definitions were the same
in cases and controls, any plausible error rate in classifying
exposed patients as unexposed would have biased our estimates
towards the null.
Although Nissen’s meta-analysis is persuasive, the generaliz-
ability of clinical trial results to the general population is often
questionable. Most studies have commonly found a non-significant
increase in risk of AMI on the order of 15% to 20% for
rosiglitazone compared to metformin. Our findings were similar in
patients who added or switched treatment from metformin, a
meaningful real- world contrast since intolerance or failure on
metformin would be the most common pathway to starting a
glitazone. A risk increase of 15% to 20% is clinically significant.
The RECORD trial, designed to evaluate the cardiovascular
safety of rosiglitazone, likely did not enroll enough patients to
detect a 15% risk increase in AMI or cardiovascular death.
In our cohort of prior metformin users, adding rosiglitazone was
not associated with an increased risk of AMI compared to adding a
sulfonylurea, or compared to adding pioglitazone. For each of
rosiglitazone and sulfonylureas separately, adding treatment with
those agents was accompanied by significantly increased AMI risk
after their initiation. It is unknown if the risk was increased due to
worsening glycemic control which led to treatment, or if the risk
was increased by more intensive treatment itself. Both hypotheses
are credible and more research is needed since they have very
different implications for treatment.
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